Deerfield Management-founded biotechnology company Aviko Radiopharmaceuticals has announced plans to advance precision boron neutron capture therapy (BNCT) to treat cancers and other diseases.

BNCT is a precision medical approach which destroys cancerous cells and reduces the impact on surrounding healthy tissues.

The company has an innovative boron medicines pipeline. These medicines are used along with low-energy, safe neutrons to enable BNCT.

Through establishing collaborations, Aviko aims to build a BNCT treatment ecosystem in the US.

Aviko CEO and Deerfield business development vice-president David Greenwald stated: “In spite of improvements in patient outcomes over the past several decades, there is still a significant need for cancer therapies that effectively target cancer cells while leaving healthy tissue unharmed.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“With Aviko, we are building on generations of innovations in medicinal chemistry, neutron research and biopharmaceutical drug development to realise the potential of BNCT to treat some of the deadliest cancers.”

BNCT begins with the administration of a non-toxic boron medicine to the patient. The medicine accumulates in cancer cells and is quickly cleared from the rest of the body.

The boron medicine stays inert until irradiated by low-energy, safe neutrons at the location of the tumour, releasing alpha particles that damage the cancerous cells selectively.

The Japanese Pharmaceuticals and Medical Devices Agency has approved BNCT to treat unresectable advanced or recurrent head and neck cancer.

Additional clinical research on BNCT is being conducted in Asia and the EU.